Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years

Urology

Volumn 51, Issue 3, 1998, Pages 389-396

  Iversen, Peter ^a   Tyrrell, Chris J ^a   Kaisary, Amir V ^a   Anderson, John B ^a   Baert, Luc ^a   Tammela, Teuvo ^a   Chamberlain, Michael ^a   Carroll, Kevin ^a   Gotting Smith, Karen ^a   Blackledge, George R p ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASTHENIA; BACKACHE; CANCER CHEMOTHERAPY; CASTRATION; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PAIN; PHYSICAL CAPACITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TREATMENT FAILURE; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; CASTRATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE; TIME FACTORS;

EID: 0032032068     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00004-1     Document Type: Article

References (29)

1. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 43:1941;209-223.
2. Kirby RS. Recent advances in the medical management of prostate cancer. Br J Clin Pract. 50:1996;88-93.
3. Fossa SD, Aass N, Opjordsmoen S. Assessment of quality of life in patients with prostate cancer. Semin Oncol. 21:1994;657-661.
4. Kaisary AV. Antiandrogen monotherapy in the management of advanced prostate cancer. Eur Urol. 31:1997;14-19. (suppl 2).
5. Kaisary AV, Tyrrell CJ, Beacock C, Lunglmayr G, Debruyne F. A randomised comparison of monotherapy with 'Casodex' 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Eur Urol. 28:1995;215-222.
6. Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT. Single agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology. 46:1995;849-855.
7. Iversen P, Tveter K, Varenhorst E. Randomised study of 'Casodex' 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scand J Urol Nephrol. 30:1996;93-98.
8. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology. 47:1996;38-43.
9. TM (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. Eur Urol. 31:1997;30-39. (suppl 2).
10. TM (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol (in press).
11. Kaisary AV. Current clinical studies with a new nonsteroidal antiandrogen, 'Casodex'. Prostate. 5:1994;27-33. (suppl).
12. Cleary PD, Morrissey G, Oster G. Health-related quality of life in patients with advanced prostate cancer: a multinational perspective. Qual Life Res. 4:1995;207-220.
13. Della Ponti U, Barichello M, Selvaggi FP, Battaglia M, Comeri GC, Conti G, Di Santo V, Montefiore F, Ferraris V, Lilliu S, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients. Preliminary results of an Italian prostate cancer group (PONCAP) study. Br J Urol. 80:1997;276. (suppl 2).
14. TM) versus combined androgen blockade (CAB): open French multicentre study in patients with metastatic prostate cancer. Br J Urol. 80:1997;283. (suppl 2).
15. Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G. Waning sexual function - the most important disease-specific distress for patients with prostate cancer. Br J Cancer. 73:1996;1417-1421.
16. Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum R. Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol. 9:1991;328-334.
17. Mazur DJ, Hickman DH. Patient preferences: survival vs quality-of-life considerations. J Gen Int Med. 8:1993;374-377.
18. Lund F, Rasmussen F. Flutamide versus stilboestrol in the management of advanced prostatic cancer: a controlled prospective study. Br J Urol. 61:1988;140-142.
19. Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol. 32:1997;391-396.
20. Pavone-Macaluso M. Flutamide monotherapy versus combined androgen blockade in advanced prostate cancer. Interim report of an Italian multicenter, randomised study (abstract 354). Proceedings of the Societe Internationale d'Urologie 23rd Congress. 1994.
21. Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, Fisher H, Rosenthal J, Witte R, Schinella R, Trump D. Double blind randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol. 14:1996;2250-2257.
22. Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti MC, Costantini M, Marotorana G, Guiliani L. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol. 146:1991;377-381.
23. Oosterlinck W, Casselman J, Mattelaer J, Van Velthoven R, Kurjatkin O, Schulman C. Tolerability and safety of flutamide in monotherapy with orchiectomy or with LHRHa in advanced prostate cancer patients. Eur Urol. 30:1996;458-463.
24. TM (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Eur Urol. 29:1996;105-109. (suppl 2).
25. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol. 155:1996;209-212.
26. Harris MG, Coleman SG, Faulds D, Chrisp P. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 3:1993;9-25.
27. McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist. 2:1997;18-27.
28. Tyrrell C. Tolerability and QOL aspects with the anti-androgen Casodex (ICI 176, 334) as monotherapy for prostate cancer. Eur Urol. 26:1994;15-19. (suppl 1).
29. Kolvenbag GJCM, Blackledge GRP. Worldwide activity and safety of bicalutamide: a summary review. Urology. 47:1996;70-79.